Sun Pharma net profit drops 20% to Rs 2,279 crore in Q1
Mumbai: Drugmaker Sun Pharmaceutical Industries reported a 20 percent year-on-year decline in consolidated net profit to Rs 2,279 crore for the first quarter ended June 30, 2025. The company had posted a net profit of Rs 2,836 crore in the same quarter last year.
Adjusted net profit, excluding the exceptional items, for the first quarter stood at Rs 2,996 crore, up 6 per cent year-on-year.
Total income rose to 14,316 crore for the June quarter as against Rs 13,185 crore in the year-ago period, Sun Pharma said in a regulatory filing.
As per PTI, Sun Pharma Chairman and Managing Director Dilip Shanghvi said the drug maker had a strong performance during the quarter, where the overall growth reflects steady progress across all its markets.
"India continues to show strong momentum, contributing meaningfully to our performance. The US launch of LEQSELVI represents an important step forward, offering a new treatment option for patients with severe alopecia areata," he added.
Sun Pharma is a specialty generics company with a presence in specialty, generics and consumer healthcare products. Sun Pharma’s global specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. Its manufacturing facilities are spread across six continents.
Read also: Sun Pharma Advanced Research Company incorporates wholly owned subsidiary Genokine Biotech
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.